Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia

Intern Med J. 2012 Jul;42(7):846-8. doi: 10.1111/j.1445-5994.2012.02827.x.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20 / immunology*
  • Diagnosis, Differential
  • Disease-Free Survival
  • Erythrocyte Transfusion
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Lymphocytosis / drug therapy
  • Lymphocytosis / immunology
  • Male
  • Middle Aged
  • Salvage Therapy* / methods

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20
  • ofatumumab